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Sepsis—a state of systemic bacterial infection—often leads to multiorgan failure and is associated with high mortality despite the
recent advances achieved in intensive care treatment. Many of the ill effects of sepsis are attributed to an abnormally enhanced
host inflammatory response that leads to neutrophil recruitment and activation involving selectins, a class of adhesion molecules,
in the initial stages. Nitric oxide and its various isoforms have also been implicated in various vascular alterations and directly
participate in the cellular toxicity in sepsis. This review briefly describes the role of selectins and nitric oxide in experimental and
clinical sepsis as well as the therapeutic outcomes of blocking therapies.
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Sepsis, a state of severe, sustained bacterial infection,
runs through phases of very low blood pressure leading to
dangerously reduced oxygen delivery to the tissues and fre-
quently to multiorgan dysfunction. . Even today, this life-
threatening complication of infection is associated with sig-
nificant morbidity and mortality in the intensive care unit,
where it is the most common cause of mortality.
Many of the adverse outcomes of severe sepsis can be
traced to an abnormally enhanced inflammatory response.
Leukocyte activation and adhesion to the endothelium in
various tissues play important roles in host defense and re-
pair of tissue damage. Under some conditions, leukocyte
adhesion to the endothelium may contribute to vascular and
tissue damage, and to organ dysfunction.
These leukcocyte-endothelial interactions, which may
also contribute to inflammation-mediated injury, involve a
group of adhesion molecules – the selectins. Because
leukocytes must adhere to the endothelium to emigrate to
the tissue, blockade of leukocyte-endothelial adhesive in-
teractions has the potential to reduce vascular and tissue
injury in sepsis and in the systemic inflammatory response
(SIRS) syndrome.1
Nitric oxide (NO) is believed to play a key role in the
pathogenesis of septic shock, although many aspects of the
involvement of NO remain poorly defined. The elevated cir-
culating nitrite/nitrate – the stable byproducts of NO ob-
served in septic patients – combined with the reduction in
vascular tone seen after endotoxin or proinflammatory
cytokine administration, and the identification of endothe-
lium-derived relaxing factor (EDRF) as NO,2 led to the sug-
gestion that NO is involved in the cardiovascular alterations
of septic shock.3 Our work has focused on elucidating the
mechanisms of action of NO and selectins in sepsis and acute
respiratory distress (ARDS). This review briefly discuses re-
cent findings on the role of selectins and NO in sepsis and
therapies directed at blocking their responses.
SELECTINS IN SEPSIS
Recruitment and activation of leukocytes in various tis-
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sues to eradicate infection remain central features in the
septic response. The interaction between complementary
adhesion molecules and ligands induced by bacterial prod-
ucts and inflammatory mediators initiate leukocyte recruit-
ment.4 Weak adhesion, or rolling, follows initial contact.
This process is predominantly mediated by selectins, a ma-
jor class of adhesion molecules involved in the earliest step
of neutrophil emigration and in the early events of the acute
inflammatory process. These molecules mediate initial con-
tact between polymorphonuclear cells and endothelial cells,
resulting in a “rolling” phenomenon, in which the
leukocytes adhere intermittently to the endothelial cells.
The selectin family is comprised of 3 proteins desig-
nated by the prefixes E (endothelial), P (platelet), and L
(leukocyte). Both E- and P-selectins are expressed by en-
dothelial cells, whereas L-selectin is expressed on
leukocytes.5 P-selectin is synthesized constitutively by en-
dothelial cells and platelets and stored in Weibel-Palade
bodies or alpha granules.6 P-selectin rapidly surfaces on
endothelial cells after activation by histamine, leukotrienes,
thrombin, oxidants, and complement.6 E-selectin, an en-
dothelial selectin, is induced by cytokines such as
interkeukin-1 and endotoxin.7 On activation by endothelial
cells, L-selectin undergoes a conformational change and,
once released, becomes a soluble protein that concentrates
in the plasma.5
The rolling leukocytes come into close contact with en-
dothelial cells, integrins, and intercellular adhesion mol-
ecules to initiate firm adhesion. The combination of these
two processes results in leukocyte binding to endothelium.
Firm adhesion of leukocytes causes endothelial damage and
allows the leukocyte to transmigrate into the surrounding
tissues.6 The uncontrolled leukocyte activation, adhesive-
ness, and sequestration in the microcirculation results in
release of toxic products such as elastase and oxygen
superoxide (O2-) and leads to endothelial damage, which
in turn leads to many of the hemodynamic and inflamma-
tory derangements that result in septic shock and, eventu-
ally, multiorgan failure (Fig. 1).8 The proinflammatory me-
diator surge in severe sepsis leads to a widespread up-regu-
lation of these adhesion molecules and may also involve
sites distant from primary infection.8 Therefore, activated
neutrophils can adhere to and damage the endothelium of
noninfected tissues as well, and leukocyte activation can
even predict outcome in septic patients. Immuno-neutrali-
zation of selectins could therefore decrease the neutrophil
adhesion and transmigration and hence, neutrophil-induced
local and systemic tissue damage.
There are several potential approaches to inhibit
leukocyte adhesion to the endothelium. The most direct
approach is to block receptor-ligand interactions.
Monoclonal antibodies of murine origin have been used
extensively in anti-adhesion therapy in a variety of preclini-
cal studies and several clinical trials.9–11 For most clinical
trials, humanized monoclonal antibodies have been devel-
oped to prevent an immune response against murine pro-
tein structures. However, small molecules that bind to the
ligand recognition site of leukocyte integrins12 and block
interaction with the surface ligands of integrins or allos-
terically modify the the receptor13 are also under develop-
ment. Another approach is to develop drugs that inhibit the
pathways involved in “inside-out” signaling of leukocyte
integrins. Antisense oligonucleotides have been developed
that target specific messenger RNAs, blocking translation
or destabilizing the message, with subsequent reduction in
surface expression of endothelial adhesion molecules such
as intercellular adhesion molecule-1.14 A more global ap-
proach is to inhibit nuclear factor-kB, a pivotal transcrip-
tion factor in the immune-inflammatory response.15 Nuclear
factor-kB regulates the expression of genes of several criti-
cal pro-inflammatory endothelial molecules such as inter-
cellular adhesion molecule-1, vascular cell adhesion mol-
ecule-1, E-selectin, and interleukin-8. Post-trafficking
events (i.e., those occurring after the leukocyte has migrated
across endothelial cells and entered tissue) are also poten-
tial therapeutic targets. Blockade of integrin receptors on
tissue leukocytes has been shown to attenuate inflamma-
tory-immune responses in animal models, perhaps by
modulating “outside in” signaling involved in leukocyte
activation or apoptosis.16,17 None of the anti-adhesion thera-
pies have, however, proven to be of any clinical benefit to
date.9-11,18-20
Of particular interest are the two traumatic-shock stud-
ies by Rhee et al.8 and Vedder et al. 19 Both trials, using
humanized CD 18 monoclonal antibodies to prevent neu-
Figure 1 - Role of selections and excessive nitric oxide in sepsis-related
tissue injury.
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trophil adhesion to endothelium, tested the hypothesis that
activated neutrophils play a pivotal role in reperfusion in-
jury after resuscitation from traumatic shock. Both trials
were prospective, placebo-controlled, randomized,
multicenter, double-blinded, phase 2 trials in patients with
blunt and penetrating trauma. Notably, although these tri-
als enrolled patients at high risk of infection, there was no
increase in infectious complications such as pneumonia in
patients receiving the humanized monoclonal antibodies to
CD 18. The trial by Rhee et al. showed a decreasing trend
in the median length of stay in the intensive care unit and
a favorable trend in the median days on the ventilator. In
those patients receiving the highest dose of CD 18
monoclonal antibodies, Vedder et al. noted a trend of im-
provement in acute respiratory distress (ARDS) syndrome
on days 1 through 3 and a significant reduction in pulmo-
nary and cardiac organ failure (Denver multiple organ fail-
ure) on day 2. However, in both trials, mortality and other
primary end points were not significantly affected. A more
recent study by Ferri et al20 concluded that elevated con-
centrations of L-selectins are found in human sepsis. A few
other studies have shown that septic patients shed L-
selectin.21 Our own experimental studies have shown that
the pulmonary microvascular response in our ARDS model
can be blocked by the administration of anti-L-selectin an-
tibody, LAM (leukocyte adhesion molecule )-(1-3), the
F(ab) 2 portion of the monoclonal antibody to L–selectin.22
However, we have also observed that the anti-P-selectin
antibody fails to prevent the activation process involved in
the deposition of leukocytes in the pulmonary microcircu-
lation (i.e. rolling or change in cellular plasticity), but this
selectin may be involved in leukocyte degranulation and
may somehow decrease peripheral oxidative tissue metabo-
lism.23 The possible reasons for failure of anti-P-selectin
antibody to prevent the activation process could be related
to the timing of its administration, since P-selectin is ex-
pressed very early in the inflammatory process. It is also
known that there are selectin-independent mechanisms of
neutrophil recruitment in the lung.
NITRIC OXIDE IN SEPSIS
Nitric oxide (NO), a ubiquitous biological molecule pro-
duced by numerous cell types, is implicated in a wide range
of disease processes, exerting both detrimental and benefi-
cial effects at the cellular and vascular levels. Sepsis is one
area where NO is thought to play a key role in
pathogenesis. Importantly, most NO research has been con-
ducted on animal models. In attempting to understand the
complexities of NO in sepsis and interpret the many ap-
parently conflicting results available, it is important to re-
member that the situation can vary according to the spe-
cies being studied, the model of sepsis employed, the con-
centrations of NO involved. Also, the timing of measure-
ments and observations may vary according to the type of
receptor blockade employed.
NO synthesis requires oxidation of a single guanidino
nitrogen atom of L-arginine, a process involving the oxi-
dation of nicotinamide adenosine dinucleotide phosphate
(NADPH) and the reduction of molecular oxygen. The ma-
jor NO synthase (NOS) isoforms identified can be broadly
grouped together as constitutive NOS (cNOS) and induc-
ible NOS (iNOS). Constitutive NOS includes nNOS (neu-
ronal NOS or NOS1) and eNOS (endothelial NOS or
NOS3). The cDNA for these isoforms has been localized
in several species, including humans. Constitutive NOS,
either neuronal or endothelial, is always present but is rela-
tively inactive until intracellular calcium levels rise. The
small amounts of NO produced by the calcium-dependent
cNOS are involved in various physiologic processes, includ-
ing neurotransmission and regulation of the vascular tone
regulation.25,27
Inducible NOS (or NOS2) is not active under normal
conditions, although the enzyme may be detected in some
cell types, including lung, small intestine, and platelets. In
sepsis, when certain cells are activated by specific
proinflammatory agents such as endotoxin, tumor necro-
sis factor alpha (TNF-alpha), interferon-gamma (IFN), and
interleukin-1 (IL-1), iNOS activity is induced. The activa-
tion of human iNOS involves transcription of messenger
ribonucleic acid (mRNA), which is triggered by the bind-
ing of transcription factors, including nuclear factor-kappa
B (NF-kB), IFN-regulatory factor-1 (IRF-1), c-jun, c-fos,
and signal transducer and activator of transcription (STAT)-
1 to specific sites on the promoter of the iNOS gene. The
activation of the newly synthesized iNOS requires post-tran-
scriptional alterations and the presence of substrate and
cofactors, including calmodulin. Calcium, although not re-
quired for calmodulin binding to iNOS, may also be im-
portant in the induction of iNOS mRNA. Once induced,
large amounts of NO are produced by iNOS, provided that
the availability of L-arginine, a substrate for biosynthesis
of NO, is available.
In addition, to the activation of iNOS, cytokines and
endotoxin may increase NO release by increasing arginine
availability through the opening of the specific channels
and through the expression of the cationic amino acid trans-
porter (CAT), or by increasing tetrahypdrobipterin levels,
a key cofactor in NO synthesis.32
The functional status of cNOS in endotoxemia and sep-
sis has not been fully elucidated. Several experimental stud-
ies have demonstrated a decrease in cNOS activity result-
74
CLINICS 2006;61(1):71-6Sepsis: emerging role of nitric oxide and selectins
Chandra A et al.
ing in an impairment in endothelial-dependent relaxation
during endotoxemia and experimental sepsis,25,26 possibly
as the result of a cytokine- or hypoxia-induced shortened
half-life of cNOS mRNA,27 or because of altered calcium
mobilization.28 Other investigators have shown increased
endothelial NO release immediately after endotoxin admin-
istration either directly29 or indirectly from the lack of ef-
fect of a specific iNOS inhibitor on the initial hypotension
after endotoxin. The activity of endothelial NO in sepsis
can actually transiently increase and then decrease later.
The pathogenic role of NO in sepsis and septic shock
can, in fact, encompass both vascular alterations and the
direct cellular toxic effects of NO or NO-related com-
pounds. At high concentrations, NO becomes a potential
proinflammatory and cytotoxic factor by reacting with O2-
to form the toxic product, ONOO- (peroxynitrite), and may
cause tissue damage (Fig. 1). In several experimental mod-
els, endotoxin has been shown to increase the constitutive
release of NO by the endothelium and the activity of the
iNOs enzyme.28 Mice lacking iNOS have been reported to
be resistant to endotoxin-induced mortality30 and vascular
hypocontractility,31 supporting a key role for iNOS in en-
dotoxin shock. In addition to endotoxin, cell wall compo-
nents and enterotoxin from gram-positive organisms are
also able to stimulate NO release.
Many experimental agents have been employed in
atempts to block the effects of NO. The first agents to be
used were competitive analogs of L-arginine. Interestingly,
the uptake of these compounds by endothelial cells and
macrophages can be influenced by cytokine or endotoxin
administration, presumably via the y+ channels.32 L-cana-
vanine, L-lysine, L-thiocitrulline, and their derivatives have
been proposed as relatively selective iNOS inhibitors. In
general, beneficial effects have been observed with inhibi-
tors which are selective for iNOS, or with low doses of non-
isoform selective inhibitors, whereas high doses of non-
isoform selective NOS inhibitors have been detrimental.
Aminoguanidine33 and L-canavanine,34 both selective in-
hibitors, have been shown to be of benefit in experimental
sepsis. Both the inhibitors provided renal and hepatic pro-
tection in addition to attenuating circulatory failure.
The role of NO antagonists has also been studied in the
clinical setting. In a study of 12 patients with severe sep-
sis, L-NMNA (N omega monomethyl-L-arginine) caused
an increase in blood pressure and systemic vascular resist-
ance with a fall in cardiac output.35 Continuous infusion
of L-NAME (N omega-nitro-L-arginine methyl ester) also
improved arterial pressure and oxygenation in septic pa-
tients.36 An increase in blood pressure and systemic vascu-
lar resistance with a decreased cardiac output in patients
receiving N nitro-L-arginine has been reported.37
Although most of these studies have reported benefi-
cial effects on hemodynamic status, NOS inhibition results
in raised pulmonary vascular resistance, and its effects on
overall outcome remain inconclusive. A recent study had
to be aborted due to high mortality in the treatment group.
More recently, it was reported that another nonselective
NOS inhibitor, 546C88, increased mortality in patients with
septic shock.38 There are studies that have indicated that
nNOS may be induced in the pathological condition.39 , We
have recently reported that 7-nitroindazole, a specific nNOS
inhibitor, reversed the pathological changes in our experi-
mental model40 We have also shown a beneficial effects of
inhibition of iNOS-derived excessive NO in our burn and
smoke inhalation injury-induced ARDS model in sheep.
Thus, the debate over whether the inhibition of NO is ben-
eficial or harmful, as well as whether the excessive amount
of NO should be suppressed, and what isoform should be
targeted, still continues. It is possible that certain NOS
isoforms could be expressed at certain time points depend-
ing on the type of injury. More targeted and selective in-
hibition of NOS isoforms using truly selective NOS inhibi-
tors at their maximal activity could be beneficial in the
management of multiorgan failure associated with sepsis.
CONCLUSION
Leukcocyte-endothelial interactions and NO are be-
lieved to play a key role in the pathogenesis of septic shock,
although many aspects of their involvement remain poorly
defined.
The selectin family of adhesion molecules mediates the
initial attachment of leukocytes to venular endothelial cells
before their firm adhesion and diapedesis at sites of tissue
injury and inflammation. Leukocyte rolling and adhesion
to endothelium is mediated in part by selectins, which not
only mediate their passive adsorption to endothelial sur-
face but also direct these processes. Also important are a
host of locally active inflammatory mediators and
chemokines responsible for initiating and perpetuating the
inflammatory process.
Selectin-directed therapeutic agents are proving to be
effective in blocking many of the pathological effects re-
sulting from leukocyte entry into sites of septic inflamma-
tion. Future studies need to be focused on how selectins
interact with the increasing array of other adhesion mol-
ecules and inflammatory mediators that are being identi-
fied.
It is now established that NO plays an important role in
the pathogenesis of ARDS, sepsis, and multiple organ fail-
ure. However, in recent studies involving animals and hu-
mans, suppression of excessive amounts of NO in sepsis has
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not proven to be of significant benefit. There is still contro-
versy on whether inhibition of NO is beneficial or harmful,
on whether NO needs to be suppressed, or which isoform is
really important. Future treatment strategies may need to be
more selective in inhibiting NOS isoforms to yield benefit.
Thus, most of the studies that attempt to inhibit the ef-
fects of selectins and NO are experimental and involve ani-
mal models, although the results of a few human (clinical)
trials are also available. To date, none of the trials has pro-
vided a definite answer in terms of elucidating the molecu-
lar mechanisms involved or in terms of showing a clinical
benefit. There is a clear need for the development of more
potent and selective receptor antagonists for more specific
selectins and specific inhibitors for NOS isoforms.
RESUMO
Chandra A, Enkhbaatar P, Yoshimitshu N, Traber LD,
Traber DL. Sepse: o papel das selectinas e do óxido nítrico.
Clinics. 2006;61(1):71-6.
Sepse – um estado de infecção bacteriana sistêmica – fre-
quentemente leva à falência múltipla de órgãos e associa-
se a altos índices de mortalidade, apesar de progressos re-
centes no manejo de pacientes em unidades de terapia in-
tensiva. Muitos dos efeitos maléficos associados à sepse são
atribuídos a uma resposta inflamatória patologicamente
ampliada que leva a recrutamento neutrofílico e ativação
das moléculas de adesão do grupo das selectinas, durante
as fases iniciais do processo . O óxido nítrico e sua diver-
sas isoformas também foram implicados nas diversas ma-
nifestações vasculares da sepse como participantes diretos
da toxicidade celular. Esta revisão descreve o papel das
selectinas e do óxido nítrico em situações clínicas e expe-
rimentais de sepse, bem como os respectivos efeitos de pro-
cessos terapêuticos de bloqueio.
UNITERMOS: Sepse. Selectinas. Óxido nítrico. Falência
múltipla de órgãos.
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